Myelodysplastic syndromes

Start here

Myelodysplastic syndromes at a glance

Myelodysplastic syndromes, or MDS, are a group of blood cancers in which the bone marrow, the soft tissue inside bones where blood cells are made, does not produce healthy blood cells effectively. Newer classifications also use the name myelodysplastic neoplasms. The marrow may contain many cells, yet too few working red cells, white cells or platelets reach the bloodstream. This helps explain why a person can have low blood counts without having an empty marrow.

MDS varies widely. Some people remain well with monitoring or treatment for anaemia (too few red blood cells) over many years. Others have disease more likely to worsen quickly or develop into acute myeloid leukaemia (AML), a faster-growing blood cancer. This does not happen to everyone with MDS. Treatment is therefore based on the exact findings, risk group, symptoms and general health. The word MDS alone does not tell you whether chemotherapy or a transplant is needed.

Symptoms and when to seek help

Low red cells can cause fatigue, breathlessness, dizziness or a fast heartbeat. Low neutrophils, a type of infection-fighting white blood cell, increase infection risk. Low platelets can cause easy bruising, nosebleeds, bleeding gums or tiny red-purple spots on the skin. Some people are diagnosed after a routine blood test before any symptoms appear.

Fever, shaking chills, severe weakness or feeling suddenly unwell requires prompt advice, particularly with low neutrophils. Heavy or persistent bleeding, black stools, severe headache after a fall, chest pain or breathlessness at rest needs urgent assessment. Do not wait for a scheduled transfusion or marrow test if symptoms become severe.

What to clarify first

Ask for the precise diagnosis, the main cause of your symptoms, the risk score being used and whether there is a reason to start treatment now. It is reasonable for a person with stable lower-risk MDS to have a monitoring plan. It is equally important not to postpone specialist assessment when immature blood cells called blasts, genetic findings or worsening blood counts suggest higher-risk disease.

Making this information useful to you

A cancer diagnosis can arrive before you have had time to understand the tests. You do not need to learn every treatment name at once. Begin with the exact diagnosis, where the cancer is, and what the team recommends next. A relative or friend can join the appointment if you would find that helpful. Ask for an interpreter when language makes a discussion harder; important decisions should not depend on guessing unfamiliar words.

This guide explains possibilities, not a prescription for your situation. Your blood and tissue test results, scan findings, general health, previous treatment and priorities determine which possibilities apply. Two people with the same cancer name may appropriately receive different treatment. If a recommendation differs from something you have read, ask the team to explain the reason and the evidence behind it.

Keep a list of medicines, allergies and other health conditions, including non-prescription products, vitamins and herbal remedies. Tell the team about previous cancer treatment, pregnancy or breastfeeding, and anything that could affect attending appointments. Do not stop an established medicine without advice. Bring your questions in the order that matters most to you, so that the most important concern is discussed first.

Understand

Blood production and abnormal clones

Blood-forming stem cells normally produce red cells that carry oxygen, white cells that defend against infection and platelets that help stop bleeding. In MDS, a group of cells acquires changes that interfere with normal development. Cells may look abnormal under the microscope, a feature called dysplasia, and may die before reaching the bloodstream.

A clone is a family of cells derived from the same original cell. Detecting a blood-cell clone does not automatically establish MDS. Clonal haematopoiesis means that an altered family of blood-forming cells has been found; clonal cytopenia means there are also low blood counts. These findings do not by themselves prove MDS. Diagnosis requires the appropriate combination of counts, marrow appearance, genetic findings and exclusion of other explanations.

Why MDS develops

For most people there is no single known cause. Risk increases with age. Some cases follow chemotherapy or radiotherapy for another illness, and these need careful classification. Rare inherited conditions can predispose to MDS, sometimes presenting in younger people or in families with unusual blood-count problems, leukaemia or related features.

Most mutations reported from a marrow sample are acquired in the diseased cells, rather than inherited by every cell in the body. If an inherited predisposition is suspected, specialist testing and counselling are important, particularly before selecting a related stem-cell donor. A relative should not be assumed to be a suitable donor simply because their tissue type matches.

Important MDS features

The marrow blast percentage describes the proportion of very immature cells. Chromosome findings, such as deletion of part of chromosome 5, and changes in genes such as SF3B1 or TP53 may help define the disease and influence treatment. Ring sideroblasts are red-cell precursors with a characteristic iron pattern seen under the microscope; they are not the same as having too much dietary iron.

Classification systems are evolving and do not use identical labels or blast thresholds in every situation. Some cases fall close to the boundary between MDS and AML, and genetic findings can change how the disease is classified. Ask the team to explain the diagnosis used for your treatment rather than trying to interpret a percentage in isolation.

Lower risk does not mean no symptoms

Lower-risk MDS can cause substantial fatigue, recurrent infection or the need for regular transfusions even when the chance of rapid leukaemic progression is relatively low. Higher-risk MDS may need disease-modifying treatment before severe symptoms appear. Treatment aims can therefore include improving daily functioning, reducing transfusions, slowing progression or pursuing cure with a donor transplant in selected people.

Tests and diagnosis

Confirming the cause of low counts

A full blood count with differential counts each main type of blood cell, including the different white cells. A blood film lets the laboratory examine their appearance under a microscope. Counts are usually reviewed over time. Tests for vitamin B12, folate, iron status, kidney function and other possible causes of low blood counts help avoid attributing a reversible problem to MDS. Copper deficiency, medicines, infection and other marrow disorders may also need consideration according to the history.

The blood count alone cannot reliably distinguish MDS from all other causes of anaemia or low platelets. A high mean cell volume, meaning larger red cells, can be a clue but is not diagnostic. Tell the team about alcohol intake, previous cancer treatment, supplements and all prescribed medicines without assuming that any one exposure is responsible.

Bone marrow and genetic testing

A marrow aspirate takes a liquid sample, while a core biopsy takes a small piece of marrow. A pathologist, a doctor who examines these samples, checks how cells develop, how many blasts are present, the structure of the marrow and any scarring, called fibrosis. Cytogenetic testing examines chromosomes; a molecular panel looks for mutations. Flow cytometry, which examines markers on individual cells, may support the assessment when the diagnosis is difficult.

The marrow is usually sampled from the back of the pelvic bone under local anaesthetic. Ask about pain relief, whether sedation is appropriate, and what bleeding precautions apply to your platelet count. The main report and chromosome or molecular results may be ready at different times. A repeat sample can be necessary if the first was inadequate or the disease changes later.

Risk scores and what they mean

The revised International Prognostic Scoring System, IPSS-R, uses marrow blasts, chromosome risk and the depth of low blood counts. The Molecular International Prognostic Scoring System (IPSS-M) also incorporates gene changes. These scores describe risk across groups and help guide treatment timing; they are not a deadline or a precise prediction for one person.

Risk assessment also considers age, other illnesses, frailty, transfusion burden and the person's priorities. A score may change if the disease evolves. Ask which score was used, what results are still missing and how the score changes the current recommendation. An intermediate category may require particularly individualised discussion rather than an automatic lower- or higher-risk pathway.

Tests that guide particular treatments

A blood level of erythropoietin (EPO), the hormone that stimulates red-cell production, can help judge the likelihood of benefit from medicines that stimulate red-cell production. Transfusion history, SF3B1 or ring-sideroblast findings, deletion 5q (loss of part of chromosome 5), and selected gene changes that medicines can target can influence the next choice. Heart, lung, liver and kidney testing may be needed before transplant or intensive treatment.

Iron overload is assessed in the context of repeated transfusions, laboratory trends and sometimes imaging. Ferritin is a blood marker of iron stores, but it can also rise with inflammation. It should not automatically lead to iron-removal treatment without considering the overall situation.

Preparing for your appointment

If scans have been performed, bring a CD containing your scan images in Digital Imaging and Communications in Medicine (DICOM) format, the standard used for medical images, together with the software needed to view them, along with the written scan reports. Bring your biopsy report and ask whether the pathology slides or tissue blocks are needed for specialist review or additional tests. Keep originals safe and agree how borrowed material will be returned. Having the actual images allows the team to compare changes and plan treatment accurately.

A repeat test is sometimes needed because an earlier sample was too small, a scan did not cover the necessary area, or a new result will change treatment. Ask what question the test will answer, how it may affect the plan, and when you should expect the result. A result described as uncertain does not automatically mean the cancer is worse. Sometimes discussion between the scan specialist (radiologist), tissue specialist (pathologist) and treating team resolves the uncertainty without another procedure.

Before a scan or procedure, mention kidney problems, previous contrast reactions, implanted devices, diabetes medicines, blood-thinning medicines and the possibility of pregnancy. Follow the testing centre's instructions about food, drink and medicines. If you have not received those instructions, contact the centre rather than making changes yourself.

Planning your treatment

Agreeing the goal of care

For lower-risk disease, the immediate priority is often relief of anaemia and fewer transfusions while preserving quality of life. For higher-risk disease, slowing progression and assessing transplant eligibility become more prominent. Supportive care remains important in every group, including during disease-directed treatment.

Ask what improvement would count as a useful response: a higher haemoglobin level, meaning more oxygen-carrying protein in the blood, fewer transfusions, better energy, lower blasts or preparation for transplant. Different treatments have different timelines. A drug that has not worked after one cycle is not always a failure, but persistent deterioration or serious side effects may require an earlier change.

Observation and transfusion planning

If counts are stable and symptoms are limited, regular monitoring may be appropriate. Agree how often blood tests and visits are needed and which symptoms should prompt earlier contact. Observation should include a clear plan rather than simply waiting for a crisis.

Transfusion decisions consider symptoms, haemoglobin or platelet levels, bleeding, heart disease and procedures. There is no single transfusion trigger suitable for every patient. Keep your blood-group and antibody history available, and report previous transfusion reactions. The team may request specially selected blood products depending on treatment and transplant plans.

Considering a donor transplant

Allogeneic stem-cell transplantation uses blood-forming cells from a donor. It is the established treatment with the potential to cure MDS. It replaces blood formation and provides a donor immune effect against abnormal cells. It also carries substantial risks, including infection, graft-versus-host disease (donor immune cells attacking healthy tissues) and treatment-related death. The decision balances those risks against the risk of the MDS itself.

Assessment should begin early enough for donor searching and fitness review when transplant may be appropriate. Age alone does not decide eligibility. Some patients receive disease-control treatment before transplant; others may proceed without a long course of therapy. The best timing is individual, and waiting until progression can make transplant more difficult.

Questions to ask your care team

• What is the exact blood cancer type and risk category, and are any important results still pending?
• Is the aim to cure the cancer, reduce the chance of recurrence, control it, or relieve a particular symptom?
• What benefit do you expect from this option, and what are the reasonable alternatives for me?
• How will treatment affect everyday activities, fertility, sexual health and the things I most value?
• How will we know whether it is working, and when will we review the plan?
• Who should I contact between visits, including at night or over a weekend?

Clinical trials and newer treatments

A clinical trial can be worth considering at diagnosis or when treatment needs to change. Trials ask a defined question; some compare established treatments and others study a newer approach. Eligibility depends on the cancer, previous treatment, test results and health. Taking part is voluntary, and choosing not to participate does not remove your right to standard care. Ask about extra visits, possible randomisation (allocation to a treatment group by chance), travel, side effects and what happens when the study ends.

Newer treatments are considered using the clinical evidence, recognised guidelines and the exact cancer type, biomarkers (features found by laboratory tests) and previous treatment. Some options have less mature evidence than established treatments. Ask what is known, what remains uncertain and whether a clinical trial would be appropriate.

Your priorities and supportive care

Tell the team what you are hoping treatment will make possible: returning to work, caring for family, keeping independence, reducing pain or attending an important event. These priorities can influence a choice between reasonable options. If the likely benefit is small and the burden is substantial, discussing a less intensive approach is appropriate. Decisions can be revisited when your health or circumstances change.

Supportive and palliative care help with symptoms, sleep, mood, family concerns and planning. They can be provided alongside treatment intended to cure or control cancer. A referral does not mean that active treatment is ending. If the cancer cannot be cured, ask what treatments may help you live longer or more comfortably and how their burdens compare with their likely benefits.

Treatment options

Medicines to improve anaemia

Erythropoiesis-stimulating agents, such as epoetin alfa or darbepoetin alfa, can help selected people with lower-risk MDS make more red cells. They are more likely to help in certain EPO and transfusion-burden groups. The team monitors response and blood pressure and decides whether to continue, adjust or change treatment. These medicines do not work for every type of anaemia.

Luspatercept helps immature red cells develop and can reduce transfusion needs in appropriate lower-risk MDS. It may be considered before or after a red-cell-stimulating medicine, depending on the treatment criteria and your disease features. Selection considers the degree of anaemia, transfusion requirements, previous treatment and disease features, including SF3B1 or ring sideroblasts. It is not a substitute for an urgently needed transfusion. Blood pressure and blood counts are monitored during therapy.

Imetelstat is another option for selected adults with lower-risk, transfusion-dependent MDS after an erythropoiesis-stimulating agent has failed, lost benefit or is unsuitable. One established treatment pathway is for low- or intermediate-1-risk MDS requiring at least four units of red cells over eight weeks. The specialist checks the exact risk category and previous treatment before recommending it. It can lower neutrophils and platelets, so counts and treatment timing need close supervision.

MDS with deletion 5q

Lenalidomide can be useful for appropriate lower-risk MDS with deletion 5q, particularly when anaemia requires transfusions. Other genetic findings and the overall risk still matter. It is not automatically the best treatment for every person whose report mentions chromosome 5.

Blood counts can initially fall, and infection or bleeding may require pauses or dose changes. Kidney function affects prescribing. Lenalidomide can cause severe harm to an unborn baby, so the pregnancy-prevention requirements apply even when treatment is for a blood condition rather than a solid tumour.

Other lower-risk pathways

Selected patients, particularly those with particular marrow and clinical features, may benefit from immunosuppressive therapy such as antithymocyte globulin with ciclosporin. This is a specialist decision and is not a general treatment for all lower-risk MDS. Hypomethylating agents, such as azacitidine or decitabine, alter chemical signals that control gene activity in abnormal marrow cells. They may be considered when other appropriate options have not helped or when disease features warrant them.

Treatment for low platelets or neutrophils is individualised. Growth factors and other supportive approaches may be useful in selected circumstances, but they should not be started simply to normalise a laboratory number. Recurrent infection, bleeding and the underlying disease pattern guide the decision.

Higher-risk MDS

Azacitidine is an established disease-modifying option for many people with higher-risk MDS. Decitabine is another option; oral decitabine with cedazuridine provides a particular oral formulation in suitable settings. Oral and injectable medicines are not automatically interchangeable, and different azacitidine formulations have different indications and schedules.

Treatment is given in repeated cycles. Blood counts may fall before improvement becomes clear, and transfusions or infection treatment may still be needed. Several cycles may be required to assess benefit when the disease remains stable enough to continue. The team follows marrow findings, counts, symptoms and transfusion needs rather than judging response by one result alone.

A fit person may be considered for a donor transplant, sometimes after treatment to reduce disease burden. Intensive AML-like chemotherapy is appropriate only for selected situations. It is not routinely better simply because it is more intensive, particularly when adverse biology or other health conditions reduce the likelihood of benefit.

Targeted treatment and disease progression

Ivosidenib can be considered for adults whose MDS has returned after a response (relapsed) or has not responded adequately (refractory), and has a susceptible change in the IDH1 gene. Testing must confirm the target. Important monitoring includes heart rhythm, interactions and differentiation syndrome, a serious inflammatory reaction as abnormal cells mature, which can cause fever, breathing difficulty, fluid retention or rapid weight gain and needs urgent assessment.

If counts worsen, transfusion needs rise or blasts increase, repeat marrow and genetic testing may clarify whether the disease has progressed or transformed to AML. Infection, medicine effects and nutritional problems can also worsen counts, so a change is not assumed to be progression without assessment. If AML develops, the treatment discussion follows the AML subtype, fitness and prior therapies.

This guide focuses on established treatment options. It does not present investigational MDS combinations as routine care. Where the best standard option is uncertain, a clinical trial can be discussed alongside supportive treatment and transplant assessment.

Supportive treatment as an active choice

Red-cell and platelet transfusions, infection treatment, symptom control and practical support can be the main treatment when disease-directed therapy offers little benefit or is not wanted. Choosing this approach does not mean that care stops. It should include a clear plan for fatigue, breathlessness, bleeding, infections and urgent contact.

Iron chelation, medicine that helps remove excess iron from the body, may be useful for selected people with ongoing transfusions and a meaningful risk from iron overload. The expected duration of treatment, kidney and liver function, transplant plans and burden of extra medicine are considered. It is not required for everyone who has ever received a transfusion.

Managing side effects

Infection and bleeding precautions

Good hand hygiene, safe food handling and avoiding close contact with people who are unwell can reduce infection exposure. The need for preventive antibiotics, antifungals or antivirals depends on treatment and immune suppression. A low white count is not a reason to begin leftover antibiotics at home. Fever during neutropenia, when infection-fighting neutrophils are low, can become serious quickly.

Use a soft toothbrush and ask about dental procedures if platelets are low. Check before taking aspirin, anti-inflammatory painkillers or supplements that can affect bleeding. Do not stop prescribed blood thinners independently; the team needs to balance clotting and bleeding risks. Persistent nosebleeds, blood in urine, black stools or new severe headaches need prompt advice.

Coping with transfusions and repeated visits

Tell staff immediately about fever, chills, rash, breathlessness or back pain during a transfusion. Similar symptoms after leaving the centre also need assessment. Some reactions occur later, and retaining a record of reactions or antibodies helps the blood bank plan future care.

Repeated visits can be tiring. Ask whether tests and consultations can be coordinated and how urgently an abnormal result will be communicated. A consistent point of contact helps when transfusions are arranged through more than one service. Share medication changes between your haematology team and other clinicians.

Side effects of disease-modifying treatment

Nausea, bowel changes, injection-site reactions and low counts can occur with hypomethylating treatment. Report symptoms early so supportive medicines can be adjusted. Oral therapy still requires careful monitoring and can cause substantial marrow suppression. Follow the prescribed calendar and call the team if a dose is missed or vomited rather than doubling the next dose.

Ciclosporin requires monitoring of kidney function, blood pressure and sometimes drug levels. Lenalidomide, luspatercept, imetelstat and targeted drugs have different safety requirements. Ask for instructions for the actual medicines you receive instead of assuming that all MDS treatments share the same side effects.

Keeping treatment manageable

Keep the team's contact details available and know where to go outside clinic hours. Report side effects early rather than waiting until the next appointment. A short record of symptoms, temperature, fluid intake and medicines can help the team decide what is needed. Do not change cancer medicine doses, restart a stopped treatment, or use leftover antibiotics without instructions. A planned delay or dose adjustment can be an important part of safe treatment.

If you receive treatment that can lower white blood cells, a temperature of 38°C (100.4°F) or higher needs urgent advice. Follow any lower threshold or additional instructions your team gives you. Chills, sudden weakness, confusion or feeling very unwell also need urgent assessment, even without a fever. Do not wait for a blood test appointment or try to hide the fever with medicine before speaking to the team.

Severe breathlessness, chest pain, a new seizure, sudden weakness, heavy bleeding or collapse require emergency care. New severe back pain with leg weakness, numbness around the bottom, or loss of bladder or bowel control also needs immediate assessment. Contact the nearest emergency service when necessary; a website contact form or routine messaging service is not an emergency pathway.

Eating, drinking and energy

Treatment may change appetite, taste, bowel habits and energy. Small, frequent meals and foods containing protein can be easier than large meals. Ask for dietitian support if weight is falling, swallowing is difficult, or you are avoiding many foods. There is no single diet that treats cancer, and severe restriction or prolonged fasting can make it harder to tolerate treatment. Check supplements with your team because some interact with medicines.

Take anti-sickness medicine as prescribed and report vomiting that prevents you keeping down fluids or essential medicines. Seek advice for persistent diarrhoea, dizziness, very little urine or increasing weakness. Fluid recommendations may need adjustment if you have heart or kidney disease. Mouth ulcers, pain or infection that interferes with eating should be treated promptly rather than accepted as unavoidable.

Gentle movement, short walks and planned rest may help fatigue, but activity should match your condition and any surgical or bone-safety restrictions. Fatigue can also reflect anaemia, infection, hormone changes, pain, poor sleep or low mood. Let the team assess a marked or persistent change. Accepting help with shopping, transport or meals can conserve energy for the activities that matter to you.

Live well

Follow-up and changing risk

Follow-up usually centres on symptoms, blood counts and transfusion needs. A marrow examination may be repeated when it will clarify response or a possible change in the disease, rather than at every visit. Ask what changes would lead to a new risk assessment or a transplant discussion.

Keep a short record of energy, breathlessness, bleeding and infections. It can help the team see whether a higher haemoglobin translates into feeling better or whether another problem needs attention. Fatigue can have several causes, including sleep disturbance, heart disease, low mood and medicines.

Activity, nutrition and everyday life

Gentle activity within your capacity can preserve strength. Adapt exertion when anaemia causes breathlessness, and avoid activities with a high injury risk when platelets are very low. Balanced food supports health, but no diet has been shown to reverse the abnormal marrow clone. Do not take iron simply because you have anaemia; repeated transfusions may already have increased body iron.

Vaccinations and routine screening remain important, with timing tailored to immune suppression. Ask before receiving a live vaccine. Travel can be possible for some people if transfusion timing, access to urgent care and infection precautions are planned in advance. Discuss these plans before making arrangements during an unstable phase of disease.

Emotional and practical support

Feeling frightened, angry, sad or uncertain is understandable. You do not have to appear positive all the time. Ask about counselling, psycho-oncology (support for the emotional effects of cancer), support groups or a social worker if worry is affecting sleep, relationships or daily life. Persistent depression, panic or thoughts of self-harm need prompt professional help. Caregivers may need their own support and breaks; one person should not have to manage every appointment and household task alone.

It can help to agree who will update relatives and how much information you want shared. Children usually benefit from honest, age-appropriate explanations and reassurance about who will care for them. Ask permission before discussing private medical information with others. If concentration or memory is difficult, use reminders, a calendar and a trusted companion at important consultations.

Relationships, fertility and sexual health

Cancer and treatment can affect desire, comfort, fertility, body image and confidence. These are valid medical concerns. Raise fertility questions before treatment when possible, because some protective options need to be arranged early. The right approach depends on age, the treatment and how urgently it must start. Do not assume that absent periods or reduced fertility means pregnancy is impossible. Ask about contraception and the safe timing of pregnancy for your specific medicines.

Explain any pain, dryness, erection difficulties or changes in intimacy to the team. Appropriate treatments, rehabilitation and counselling can help. You can choose how much to involve a partner. Advice about hormone-containing treatments needs to take the cancer type and treatment into account; do not start them without discussing suitability.

Planning ahead while living well

Ask for a clear follow-up plan and know which symptoms should be reported between visits. Continue care for other conditions and discuss vaccinations with your oncology team; the timing and suitability of live vaccines can change during treatment. Avoid tobacco and ask for practical cessation support if needed. Activity, food and sleep plans should be realistic for your health rather than another source of pressure.

If treatment is long term, arrange periodic discussions about what is helping, what is difficult and what you want next. Planning for future care can protect your preferences and reduce uncertainty for family. You can discuss who should help with decisions if you become too unwell to speak for yourself, while continuing treatment and everyday life now.

Related care

Explore treatments

Medical Oncology↗Ports, PICCs, and venous access↗Stem Cell Transplant & Cellular Therapy↗Radiation Oncology↗Cancer Diagnostics & Molecular Testing↗Supportive & Holistic Cancer Care↗

Meet our doctors

Dr (Prof) Vijay Agarwal

Professor and Lead Consultant – Medical Oncology

Dr Prathyush V

Senior Consultant – Medical Oncology & Haemato-Oncology

Dr Darshan R S

Consultant – Medical Oncology & Haemato-Oncology

Where to get care

Bannerghatta Road

Apollo Hospitals
Bengaluru

Seshadripuram

Apollo Hospitals
Bengaluru

Sarjapur

Apollo Hospitals
Bengaluru

Jayanagar

Apollo Speciality Hospital
Bengaluru